Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ardelyx, Inc. logo — Translating Scientific Breakthroughs into Promise for Patien...

Ardelyx, Inc.

Translating Scientific Breakthroughs into Promise for Patients

Founded 2007 United States Waltham, United States 378 employees Post-IPO Debt Total: $557.68M Biotechnology, Health Care

General Information

Company Name Ardelyx, Inc.
Founded Year 2007
Location United States Waltham, United States
Founders / Decision Makers
Team member
Employees 378
Industries Biotechnology, Health Care
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Ardelyx, Inc.. To contact Ardelyx, Inc., visit ardelyx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Ardelyx, Inc.

Ardelyx, Inc. is a biotechnology company with a compelling mission to develop groundbreaking medicines that address critical unmet medical needs. The company's slogan, "Translating Scientific Breakthroughs into Promise for Patients," reflects its dedication to leveraging scientific advancements for patient benefit. Founded in 2007, Ardelyx has made significant strides in the field of biotechnology and healthcare. The company has received a recent investment of $20.00M in Post-IPO Debt, with HealthCare Royalty Partners and Kyowa Kirin as the investors. This investment underlines the confidence that these key players in the healthcare industry have in Ardelyx's potential. With a focus on innovation, Ardelyx has successfully launched two products, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) in the United States, addressing critical medical needs. Moreover, Ardelyx has formed strategic partnerships for the development and commercialization of tenapanor outside of the U.S., with Kyowa Kirin commercializing PHOZEVEL® (tenapanor) in Japan, and a New Drug Application for tenapanor for hyperphosphatemia being submitted in China with Fosun Pharma. In Canada, Knight Therapeutics is commercializing IBSRELA. Ardelyx's commitment to addressing unmet medical needs and its successful commercialization efforts demonstrate its potential for growth and impact in the biotechnology and healthcare sectors. As the company continues to advance its early-stage pipeline candidates, it stands as an exciting prospect for potential investors seeking to contribute to transformative innovation in healthcare.

Taxonomy: biopharmaceuticals, drug development, mineral metabolism, metabolic disorders, oral therapeutics, NHE3 sodium transport inhibitor, intestinal health, IBS-C treatment, hyperphosphatemia treatment, chronic kidney disease, type 2 diabetes treatment, venture funding, angel funding, pharmaceutical marketing, clinical trials

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $20.00M 2
HealthCare Royalty Partners
HealthCare Royalty Partners, Kyowa Kirin
30 Jun 2022
Post IPO Debt $27.50M 1
SLR Capital Partners
24 Feb 2022
Post IPO Equity $125.00M -
12 Dec 2019
Post IPO Debt $50.00M -
21 May 2018
Post IPO Equity $110.00M 10
New Enterprise Associates RA Capital Management EcoR1 Capital
New Enterprise Associates, RA Capital Management +8
18 Jul 2016
Post IPO Equity $86.30M -
06 Jan 2016
Post IPO Equity $77.77M 7
New Enterprise Associates RA Capital Management Foresite Capital
New Enterprise Associates, RA Capital Management +5
22 Jun 2015
Series B $30.00M 3
New Enterprise Associates Amgen Ventures CMEA Capital
New Enterprise Associates, Amgen Ventures +1
31 Aug 2011
Debt Financing $5.01M -
16 Nov 2010
Series A $26.09M 1
CMEA Capital
CMEA Capital
12 Jun 2008

Ardelyx, Inc. Alternatives & Competitors

View All Alternatives
Ardelyx, Inc. vs
Fractyl Health
Fractyl Health United States

Dedicated to novel therapies that can sustain long term weight management.

Series F
104 employees
Biotechnology, Health Care
Ardelyx, Inc. vs
DiObex
DiObex

Innovative biotechnology solutions for metabolic disorders.

Series B
Biotechnology, Health Care
Ardelyx, Inc. vs
vTv Therapeutics
vTv Therapeutics United States

Committed to Improving the Lives of Patients with Diabetes

Post-IPO Equity
50 employees
Biotechnology, Health Care
View all alternatives

FAQ About Ardelyx, Inc.

Translating Scientific Breakthroughs into Promise for Patients
Ardelyx, Inc. was founded in 2007.
Ardelyx, Inc. is headquartered in Waltham, United States.
Ardelyx, Inc. operates in Biotechnology and Health Care. Its work centres on biopharmaceuticals, drug development, mineral metabolism and metabolic disorders.
Ardelyx, Inc. has approximately 378 employees.
Ardelyx, Inc. has completed 10 funding rounds, raising a total of $557.68M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Ardelyx, Inc. include Fractyl Health, DiObex, vTv Therapeutics, THRASOS LIMITED, Gan & Lee Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ardelyx, Inc. and Fractyl Health are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ardelyx, Inc., https://bouncewatch.com/company/ardelyx-inc, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes